For the first stage of cuts, which calls for an immediate $1 trillion over a decade in exchange for raising the debt ceiling by an additional $900 billion, imaging reimbursement was spared. But that might not be the case for the second stage, according to ACR.
President Obama and congressional lawmakers have agreed on major spending cuts as a part of the debt ceiling deal aimed at staving off a financial default.
The cuts are to happen in two stages. For the first stage, which calls for an immediate $1 trillion over a decade in exchange for raising the debt ceiling by an additional $900 billion, imaging reimbursement was spared. But that might not be the case for the second stage, according to ACR.
The second round of $1.4 to $1.5 trillion in cuts will be identified by a bipartisan “super committee” of House and Senate members. The group is expected to submit its recommendations at the end of November, and those recommendations could include cuts to Medicare, notes Aubrey Westgate at DI's sister publication, Physicians Practice.
“Although successful in averting any cuts associated with the initial $900 billion debt ceiling increase, ACR anticipates that the 12-member super committee undoubtedly will consider changes in Medicare physician reimbursement rates to cut costs,” according to the ACR. “Cuts to imaging will likely be part of a larger package of physician reimbursement reductions.”
If the committee doesn’t reach an agreement, $1.2 trillion in automatic cuts would be applied across the board, and Medicare would be included.
ACR vowed to continue educating lawmakers about “why further cuts to imaging are unnecessary and will adversely impact patient care.”
Have you been following the debt ceiling debate? Are you concerned it could impact imaging? Tell us what you think.
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.
Expanded FDA Approval Allows Use of Pluvicto Prior to Chemotherapy in Patients with mCRPC
March 28th 2025Recent research demonstrated a 59 percent reduced risk of progression or death with the radioligand therapy Pluvicto in comparison to a change of androgen receptor pathway inhibitor (ARPI) for patients with metastatic castration-resistant prostate cancer (mCRPC).
New AI-Enabled Portable Ultrasound May Facilitate 50 Percent Reduction in Cardiac Imaging Scan Time
March 28th 2025Artificial intelligence (AI)-powered measurement capabilities provide key features with the Compact Ultrasound 5500CV device, which will be unveiled at the American College of Cardiology (ACC) conference.